ORG Wealth Partners LLC Purchases Shares of 8,469 Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

ORG Wealth Partners LLC acquired a new position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in the 3rd quarter, HoldingsChannel.com reports. The fund acquired 8,469 shares of the biopharmaceutical company’s stock, valued at approximately $40,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Sei Investments Co. grew its position in Vanda Pharmaceuticals by 39.6% in the 1st quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company’s stock valued at $2,132,000 after buying an additional 147,066 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of Vanda Pharmaceuticals in the first quarter valued at approximately $1,158,000. Acadian Asset Management LLC increased its stake in shares of Vanda Pharmaceuticals by 4.7% during the first quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company’s stock valued at $9,740,000 after acquiring an additional 107,203 shares during the period. Monaco Asset Management SAM bought a new stake in Vanda Pharmaceuticals during the second quarter worth approximately $1,090,000. Finally, Empowered Funds LLC raised its holdings in Vanda Pharmaceuticals by 8.2% during the first quarter. Empowered Funds LLC now owns 201,283 shares of the biopharmaceutical company’s stock worth $827,000 after purchasing an additional 15,215 shares in the last quarter. 88.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Cantor Fitzgerald increased their price target on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. StockNews.com assumed coverage on Vanda Pharmaceuticals in a research note on Wednesday. They set a “hold” rating for the company.

Vanda Pharmaceuticals Price Performance

Shares of VNDA opened at $4.80 on Wednesday. The firm’s 50 day moving average is $4.97 and its 200-day moving average is $5.22. Vanda Pharmaceuticals Inc. has a 12-month low of $3.30 and a 12-month high of $6.75. The stock has a market capitalization of $279.35 million, a P/E ratio of -60.00 and a beta of 0.77.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $50.47 million during the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. As a group, equities research analysts forecast that Vanda Pharmaceuticals Inc. will post -0.49 EPS for the current fiscal year.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.